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Abstract 
 
Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been proposed to be effective at treating 
COVID-19 patients. We, and others, have previously reported on the capacity of CQ to reduce HIV-1 
replication in vitro. We tested CQ administration in post-partum mothers on influencing HIV-1 viral 
loads in human milk as a means of lowering mother to child transmission. A Phase I/II, randomized, 
placebo-controlled study to evaluate chloroquine administration to reduce HIV-1 RNA levels in 
human milk: the CHARGE study. Thirty HIV-1 positive pregnant Rwandese women (CQ n = 20; 
placebo n = 10) were enrolled in a 16-week study, with the treatment group receiving a 200 mg oral 
dose of CQ daily. Base-line plasma viral load (pVL) measurements and CD4 counts were determined 
prior to delivery, and pVL, breast milk VL (bmVL) and CQ levels measured during treatment. For 
women receiving treatment, CQ concentration was higher in breast milk compared to plasma (over 
2.5-fold), with a positive correlation between the levels in the two compartments (P < 0.003). A link 
between high CQ concentrations in plasma and high CD4 counts (P < 0.001) was observed. 
Surprisingly, we found a significant increase in pVL after CQ treatment in over half of the mothers 
(n=11; P < 0.001) and with no alteration to bmVL measurements. No specific amino acid alterations in 
the gp120 envelope sequences could be associated with CQ administration. CQ usage is associated 
with a significant increase to pVL in early breastfeeding mothers from Rwanda which cautions against 
the use of CQ in such individuals. Our results highlight a discrepancy between CQ effects on 
modulating HIV-1 replication in vitro versus in vivo and indicate caution when prescribing CQ to post-
partum HIV-1 untreated mothers. This discrepancy should be taken into consideration when testing 
CQ or HCQ treatment in COVID-19 clinical trials, especially relating to the post-partum setting. 
Keywords: HIV-1, CQ, HCQ, post-partum, randomized placebo-controlled trial 
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Introduction 
The extent of COVID-19 disease (SARS-CoV-2) has accelerated efforts to identify readily-available, 
safe and effective treatments or vaccines. Given its antiviral properties, studies are investigating the 
effectiveness of chloroquine (CQ) and hydroxychloroquine (HCQ) to treat people with confirmed 
coronavirus infection.  
Chloroquine and HCQ are cheap, widely available and have been shown to reduce HIV-1 
replication in vitro and in vivo [1-5]. We have previously shown that CQ can interfere with virus 
replication in CD4+ T lymphocytes and that the inhibition is likely conferred at the cellular level [6]. It 
has been shown that CQ treatment can interfere with the potential N-linked glycosylation (PNG) 
pattern of the gp120 envelope protein with the reported modulation of the 2G12 monoclonal antibody 
epitope [1] and the capacity by which HIV-1 can undergo viral transfer to CD4+ T lymphocytes via 
cells expressing DC-SIGN in vitro [6]. The endosomal pH increases with CQ treatment and is believed 
to reduce IL-6 production [7], thereby causing a down-regulation of HIV-1 production in chronically 
infected T-cells and monocyte cell lines [2,8]. Several clinical trials have previously shown that CQ 
and HCQ treatment can reduce pVL in vivo with no effect on CD4 counts [3,4].  
Mother to child transmission of HIV-1 (MTCT) can occur either in-utero, intra-partum or via 
breastfeeding [9-11]. Transmission of HIV-1 to the infant via breastfeeding has been associated with 
high pVL and breast milk VL (bmVL), low CD4 count and the presence of sub-clinical mastitis 
[13,14]. CQ has been shown to be secreted in human milk [15-17] suggesting it may be effective at 
lowering bmVL. The presence of CQ in human milk has also been shown to be non-toxic to children 
[18], making it ideally suitable for such a purpose. This study was undertaken to test whether CQ 
treatment of HIV-1 infected breastfeeding mothers could be effective at lowering VL and potentially 
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limiting MTCT, and may provide valuable lessons for its effect with other viral infections, such as 
SARS-CoV-2.  
Methods 
Study design, Participants and clinical evaluations  
Between 2000-2001, we conducted a phase I/II randomized placebo-controlled pilot trial undertaken in 
Rwanda with 30 HIV-1 breastfeeding mothers randomized (2:1) to receive oral CQ 200 mg once daily 
or placebo (Pl) for 16 weeks (wks). All women received single-dose nevirapine (200 mg) at start of 
labor and children received single-dose nevirapine within 72 hrs. The study was approved by all the 
appropriate Ethic Committees (IEC) in both the Netherlands, the STEG-METC (ref no R01-089) and 
Rwanda and informed consent was obtained for all mothers. The CQ capsules, and matched placebo 
capsules, were prepared at the pharmacy department of the Slotervaart Hospital, Amsterdam, and 
concealed to the investigators I Rwanda (double-blinded). Patients were randomized on day 1 of 
breastfeeding (wk0) and the study un-blinded at wk18. All participants were confirmed HIV-1 infected 
(rapid tests), at least 18 years of age, therapy-naive, between 32-35 wks gestation and had not received 
CQ in the six wks prior. Pre-screen (psc) with follow-up and counseling visits were scheduled at wk0 
(delivery), wk4, 8, 16, 17 and 18. All pVL were assessed at psc, wk0, 8 and 16 and bmVL at wk0, 8 
and 16 and in both breasts. CQ concentrations were measured in blood plasma and from right (RB) 
and left (LB) breasts at wk0, 8 and 16. Both pVL and bmVL measurements were determined using the 
Roche diagnostics HIV-1 RNA PCR quantification assay.  
Measuring CQ concentrations  
To 1.0 ml plasma (supplemented with CQ free plasma if required) in a glass conical tube, 25 µl of 
internal standard solution (50 µg/ml diaminonaphthalene in methanol), 1 ml of 1M sodium hydroxide 
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and 6 ml diethylether were added. After shaking for 10 min, the mixture was centrifuged for 5 min at 
ca. 2x103 g. After storage of the tube for 1 h at -30°C, the organic layer was poured into a second tube 
and evaporated at 40°C under a gentle stream of nitrogen. Finally, the residue was reconstituted in 
200 µl eluent using vortex-mixing and 50 µl was injected onto the HPLC. To 1.0 ml milk 
(supplemented with drug-free cow milk if required) in a glass conical tube, 6 ml n-hexane was added. 
The tube was shaken for 10 min and centrifuged for 5 min at ca. 2x103 g. After storage of the tube for 
1 h at -30°C, the organic layer was discarded. After thawing the aqueous layer, 1 ml of 1M sodium 
hydroxide and 6 ml diethylether were added and the procedure was continued according to the pre-
treatment of plasma samples. Chromatographic conditions: Fifty µl injections were made on a 
Symmetry C18 column (100×4.6 mm, dp = 3.5 µm, average pore diameter = 10 nm, Waters), protected 
by a Symmetry C18 pre-column (20×3.8 mm, dp = 5 µm, Waters). The column temperature was 
maintained at ambient temperature (23-29°C). The eluent comprised 9% (v/v) acetonitrile and 91% 
(v/v) phosphate buffer (45 mM, pH 3.0) and the eluent flow rate was 1.0 mL/min. The UV detection 
wavelength was 340 nm. 
PCR amplification and sequencing of gp120  
Viral RNA was isolated from serum and the C1C4 gp120 region amplified by RT-PCR as previously 
described with the appropriate primers [19]. PCR products were cloned into the TOPO II vector 
(Invitrogen) and sequenced bi-directionally using the BigDye Terminator Cycle Sequencing kit (ABI). 
Primers A1360 GAG CCA ATT CCY ATA CAT TAT TG, SP6 ATT TAG GTG ACA CTA TAG and 
T7 TAA TAC GAC TCA CTA TAG GG were used for sequencing. Subtype determination and 
phylogenetic analysis was performed with the neighborhood-joining (N-J) analysis of MEGA [20]. 
PNG sites were determined using Glycosite (http://hiv-web.lanl.gov/content/hiv-
db/GLYCOSITE/glycosite.html). 
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Statistical analysis  
Descriptive statistics for group comparison and regression analyses were performed utilizing the Prism 
package software (GraphPad software Inc., San Diego, California, USA, version 4.0). All available 
CD4 T cell counts, pVL and CQ level data were utilized, with the pVL values Log10-transformed. The 
Mann Whitney or the Wilcoxon signed rank tests were applied appropriately and the level of 
significance was set at P = 0.05.  
Results 
Clinical parameters of study individuals  
The study participants are described in Table 1 (Placebo: n = 10, CQ: n = 20) and with a study 
schematic shown (Fig. 1). Of the 30 study individuals enrolled 7 did not finish due to early termination 
of breastfeeding or death of the child (Placebo: n = 5, CQ: n = 2). Infant pVL measurements taken at 
wk16 identify 6 infants to be infected, 1/5 in the Placebo group and 5/18 in the CQ group. From gp120 
V3 region PCR analysis at wk0 we identified 3 infants to be HIV-1 positive at time of delivery with 
the remaining 3 infected either peri-partum or during the early breastfeeding period. Interestingly, the 
highest wk16 pVL were in those HIV-1 positive at time of delivery.  
CQ concentrations in breast milk are higher than in plasma 
No differences in mean CD4 counts were identified between the Placebo and CQ groups at either wk0 
or wk16, or between the different wks for both groups. The mean CQ concentration in plasma at wk8 
is 759.7ng/ml (244-877ng/ml) and at wk16 478.2ng/ml (174– 414ng/ml). Of note, there was an 
association between high plasma CQ concentrations at wk8 with high CD4 counts, with those 
harboring concentrations of CQ over 1,200 ng/ml having the highest CD4 counts (P < 0.0001) but 
which did not correlate with pVL at wk16 (data not shown). CQ levels in breast milk are higher than in 
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plasma at both wk8 and wk16 (Fig. 2a) with a positive correlation between CQ levels in plasma and 
breast milk at wk8 and wk16 (Fig. 2b). In summary, CQ levels are higher in breast milk than in plasma 
and at wk8 the CQ levels are on average 2.5 fold higher in breast milk. 
CQ treatment results in increased plasma but not breast milk HIV-1 viral loads 
Mean pVL for CQ and Placebo groups are shown in Fig. 3a and 3c, respectively. No differences were 
observed between psc and wk0 or wk8 and wk16 for either group. The pVL values were, however, 
higher in the Placebo group compared to the CQ group at both psc and wk0 (2.5- and 2.1-fold, 
respectively). When comparing pVL measurements before and after treatment we observed a 
significant increase in the CQ group between psc and either wk8 or wk16 (P < 0.001) as well as wk0 
and the later time-points (P < 0.001) (Fig. 3b). The mean pVL in the CQ treated group shows an 
increase of 1.0 log after wk8. Similar conclusions are drawn when we calculate the fold increase in 
pVL between wk8/wk0 or wk16/wk0, shown in Table 1 and Fig. 3b. The results show that over half of 
the CQ treated individuals harbor large increases in pVL by wk8, with the others showing little 
changes. We found bmVL to be consistently lower than pVL with many below the detection limit and 
with no differences between the CQ and Placebo groups (Fig 3a and 3c, respectively). When we 
compare the pVL with the bmVL in the CQ group we find a positive correlation (P<0.05). We also 
observe no difference in bmVL fold increase when comparing wk8 or wk16 with psc or wk0 for either 
the CQ or Pl group (Fig. 3b and Fig. 3d, respectively). 
gp120 envelope genetic analysis before and after CQ treatment 
Since we have previously reported genetic changes in the envelope of viruses passaged in the presence 
of CQ [6], we analyzed the gp120 C1C4 region DNA sequences in plasma from Pl (n = 4) and CQ 
individuals (n = 10) as designated in Table 1, before and after treatment (wk16). When comparing the 
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overall amino acid charge of the V1V2 region we identified an increase over time for both the Pl and 
CQ treated groups and for the CQ treated individuals we found a link with increased pVL (P = 0.028), 
which was not observed for the Pl group. The V3 charge, which has been linked to coreceptor usage 
[21,22], was found to increase in 5/10 of the CQ treated individuals versus 1/4 of the Pl group, but was 
not statistically significant nor could be linked to increased pVL. A similar observation was found in 
the V4 regions. When comparing the alterations to the length of the variable regions no differences 
were found for either the Pl or CQ treated groups or with higher pVL in the CQ group. Similarly, 
alterations in the number of PNG sites did not alter in any of the variable regions in either the Placebo 
or CQ groups or between wk0 and wk16 of CQ treated individuals where pVL increased. Collectively, 
the results indicate no strong selection pressure exerted by CQ during the 16-week study period.  
Discussion 
High levels of CQ could accumulate in both plasma and breast milk, with substantially higher levels 
accumulating in breast milk. CQ treatment did not correlate with reduced HIV-1 bmVL, but 
surprisingly, did associate with increased pVL at both wk8 and wk16. This is in stark contrast to 
previous reports which have described decreases in pVL after CQ treatment [3,4]. Given the CQ 
concentration administered and a previous study showing that the drug dosage prescribed correlates to 
HCQ blood levels [23] it is unlikely that we have reached insufficient concentrations of the drug. 
Although the majority of in vitro studies to-date have described lower replication of HIV-1 in the 
presence of CQ, one study has indicated that high concentrations of CQ can be associated with 
increased viral entry [24]. It should also be noted that in animal models for various virus infections, 
including Semliki Forest Virus (SFV), CQ treatment can result in increased viral replication and 
modulate cytokine responses in vivo [25].   
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It has been reported that CQ treatment can decrease the glycosylation pattern of the HIV-1 gp120 
protein [1]. When we compare the alterations to gp120 sequences from before and after CQ treatment 
we did not observe any major alteration to the V1-V2, V3 or V4 sequences, suggesting that CQ had no 
effect on selecting variants with altered replication phenotypes. Although glycosylation differences 
were not observed at the amino acid level it does not rule out the possibility that post-translational 
modification differences account for the results obtained i.e. altered recognition of HIV-1 by the 
neutralizing antibody repertoire leading to immune escape.  
CD8+ T-lymphocyte responses have been shown to be modulated by CQ treatment, with higher 
levels of cellular activation mediated through an increase in antigen presentation by MHC class-I 
molecules [26]. The same scenario may hold true for CD4+ T-lymphocytes with an increase in 
antigenic presentation via MHC class-II molecules by antigen presenting cells, resulting in heightened 
cellular activation and increased viral replication. This, however, would not explain the lack of 
increase in pVL in previous CQ or HCQ studies [3,4]. The present results support a recent study where 
mothers receiving CQ did not show a decrease in pVL or bmVL [27]. The previous studies with CQ 
and HCQ have all been performed on male participants and we cannot rule out gender effects or 
differences due to child birth and/or lactation. It has been shown that bacterial translocation from the 
gut can be associated with heightened immune activation in HIV-1 infected individuals [28]. Whether 
CQ can influence bacterial growth in the gut or at the vaginal mucosa and ultimately modulate 
immune activation in treated mothers soon after delivery needs to be studied. It has been suggested CQ 
can restrict signaling via the toll like receptor 9 (TLR9), however, it has also been shown that with 
intestinal epithelial cells, CQ can augment cellular activation and thereby possibly upsetting colonic 
homeostasis [29].  
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It has been hypothesized that CQ could be used as a safe and cheap alternative to conventional 
HIV-1 antiretroviral pMTCT regimes and has been considered for use in resource-limited settings. 
More recently chloroquine as well as hydroxychloroquine treatment has been advocated for inhibiting 
SARS-CoV-2 replication and treating COVID-19 patients. Our results indicate caution when treating 
HIV-1 positive women in the post-natal period with CQ and especially those soon after childbirth 
where the likelihood of HIV-1 transmission through breastfeeding is present. Increased HIV-1 viral 
loads in mothers receiving CQ, opposed to the drugs observed inhibitory effects in vitro, provide 
caution in prescribing the drug as an effective antiviral to all patients. Increased viral loads in plasma 
of post-partum mothers may reflect hormonal effects which have been shown to associate with 
modulation of immune responses and where CQ treatment may have an effect on influencing HIV-1 
activation and replication [30]. It has also been documented that CQ can have differential effects on 
activation of transcription factors, such as through NF-κB, with the potential to induce pro-
inflammatory responses [31], with the potential consequences of increasing HIV-1 replication and 
plasma viral loads.  
Several commentaries have proposed using CQ and HCQ to treat coronavirus COVID-19 as part 
of a ‘drug repositioning’ strategy [32-39]. CQ has displayed in vitro activity against the SARS-CoV-1 
[40-43]. Middle East respiratory syndrome coronavirus (MERS-CoV) [44], human coronavirus 229E 
(HCoV-229E) [45] and HCoV-O43 [46,47]. While both HCQ and CQ display in vitro activity against 
SARS-CoV-2 [48,49], the evidence proposes HCQ as potentially exhibiting a stronger in vitro anti-
SARS-CoV-2 activity, of the two drugs. The in vivo evidence is less distinct in that a study treating 
confirmed coronavirus patients with HCQ sulphate outperformed the control group [23] whereas a 
Shanghai [25] study reports the control having a slightly better outcome. It is apparent that more studies 
are required to inform the use of CQ or HCQ for SARS-CoV-2 treatment. Our findings of increased 
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HIV-1 pVL with CQ in post-partum women should be taken into consideration when designing or 
administering CQ or HCQ in COVID-19 clinical trials, especially relating to the post-partum setting. 
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Figure Legends 
Fig. 1. Schematic of the proposal study design. 30 mothers were enrolled with 20 belonging to the 
treatment arm and 10 to the placebo group.  
Fig. 2. CQ levels after treatment. (a) CQ levels in the plasma, left breast and right breast of each 
study individual at wk8 and wk16 of treatment, with mean values depict. (b) correlation between 
plasma CQ levels and milk CQ levels at wk8  
Fig. 3. HIV-1 viral load measurements before and after CQ treatment. (a) mean HIV-1 viral load 
measurements for plasma, LB and RB at psc, wk0, 8 and 16 for the CQ treated individuals (b) fold 
increase in viral load measurements in plasma, LB and RB between different weeks for the CQ treated 
individuals (* P < 0.05, ** P < 0.005) (c) mean HIV-1 viral load measurements for plasma, LB and 
RB at psc, wk0, 8 and 16 for the Pl treated individuals (d) fold increase in viral load measurements in 
plasma, LB and RB between the different weeks for the Pl treated individuals. 
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Table 1 Study individuals       
 
 
 Code Gp   Subtype Inf pVL pVL Code Gp Subtype Inf pVL pVL 
     wk8/0 wk16/0     wk8/0 wk16/0 
  
 060 Pl       A* 0 sna 1.3 020 CQ n/d 0 44.0 2.3 
 090 Pl       A* 750,000+ sna 0.8 030 CQ A 0 37.6 10.1 
 100 Pl      A sna 0.4 sna 040 CQ A 0 1.6 0.1 
 110 Pl       A* 0 sna 4.2 050 CQ A* 0 18.5 27.8 
 150 Pl     A 0 0.7 sna 130 CQ C* 7,590 0.6 0.6 
 200 Pl       A* 0 0.1 0.3 160 CQ A* sna 0.8 sna 
 240 Pl      n/d 0 1.5 1.6 180 CQ C 0 0.2 1.4 
 260 Pl      A 0 0.6 sna 190 CQ C* 0 19.7 15.6 
 280 Pl       A 0 1.1 sna  210 CQ C 0 37.5 52.3 
 400 Pl      A sna 4.3 sna 220 CQ A 0 1.3 sna 
       250 CQ A/C* 269,000+ 7.2 5.0 
       270 CQ C 0 1.8 2.3 
       290 CQ C* 531,000+ 16.1 121.9 
       300 CQ A* 747,000 13.1 14.3 
       340 CQ A* 0 2.8 4.1 
       350 CQ A 0 294.0 10.1 
       360 CQ A 0 1.0 1.9 
       370 CQ A* 144,000 5.9 8.6 
       380  CQ  A* 0   50.9 12.9 
         390  CQ  C 0   1.1  8.0  
    
Placebo (Pl) or CQ treated (CQ) group (Gp), subtype of infection, whether the infants are 
infected (Inf) and their pVL at wk16. Fold increase in mothers pVL of mothers between 
wk8 and wk0 (wk8/0) as well as w16 and wk0 (wk16/0).   
sna – sample not available; + - baby infected at birth; * - gp120 amplified and sequenced; 
Bold is viral load fold increase greater than 5.0. 
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Table 2. Sequence analysis of gp120 of CQ and Placebo treated group 
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Figure 1   Study Schematic 
 
 
Assessed for eligibility (n=40) 
Excluded (n=10) 
* Maculopathy (n=1) 
* Arrived late after first breast milk production (n=3) 
* No breast milk production (n=3) 
* Died before delivery (n=1) 
* Other reasons (n=2) 
In follow-up after 16 weeks (n=18) 
* Child died (n=1) 
* Injury of child’s mouth resulting in stop 
breastfeeding (n=1) 
In follow-up after 8 weeks (n=20) 
Allocated to chloroquine 200mg OD (n=20) 
* Received allocated intervention (n=20) 
In follow-up after 8 weeks (n=10) 
Allocated to placebo (n=10) 
* Received allocated intervention (n=10) 
In follow-up after 16 weeks (n=5) 
* Child died (n=2) 
* Insufficient breast milk during follow-up (n=3) 
Randomized after delivery (n=30) 
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